BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OTULFI (ustekinumab-aauz) by Fresenius Kabi is interleukin-12 antagonists [moa]. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OTULFI (ustekinumab-aauz) is a monoclonal antibody antagonist of interleukin-12, approved by the FDA on September 27, 2024. It is a biosimilar referencing the originator ustekinumab, indicated for immunological and inflammatory conditions where IL-12 inhibition provides therapeutic benefit. This injectable biologic works by blocking IL-12 signaling to reduce pathogenic immune responses.
Growth
Early-stage biosimilar in growth phase with moderate competitive pressure (30%); commercial team build-out is ongoing as market penetration accelerates.
Mechanism of Action
Interleukin-12 Antagonists
Pharmacologic Class:
Interleukin-12 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OTULFI offers entry-level to mid-career pharma professionals a rare opportunity to build a biosimilar brand from launch in a competitive but growing market segment. Roles emphasize payer strategy, managed markets, and rapid market penetration rather than clinical development.
Brand ManagerRegional Sales Manager
Worked on OTULFI at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.